New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 20, 2012
11:08 EDTDANOY, MJN, NSRGY, PFE, SYUTDanone drops following report of raised bid for Pfizer unit
Groupe Danone (DANOY) is retreating after the French food maker increased its offer for Pfizer's (PFE) infant nutrition business to close to $11B, according to Reuters, which cited the French website WanSquare. Danone is trying to outbid Nestle (NSRGY), which was nearing a deal for the Pfizer unit last week, Reuters reported, citing unnamed sources. Pfizer's infant nutrition business is growing quickly and is strong in emerging markets, with a key position in China, Reuters added. In late morning trading, Danone dropped 27c, or 1.91%, to $13.89. Pfizer (PFE) is climbing, while Mead Johnson (MJN) and Synutra (SYUT), which also sell infant formula, advanced.
News For DANOY;PFE;MJN;SYUT;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
February 24, 2015
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
February 22, 2015
17:31 EDTNSRGYNestle looks to boost productivity in Switzerland, Reuters says
Subscribe for More Information
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTPFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
06:25 EDTDANOYDanone board to ask shareholders to approve increased dividend of EUR1.50
Subscribe for More Information
06:24 EDTDANOYDanone targets 2015 organic growth in sales of between 4%-5%
Danone assumes that economic conditions will remain difficult and unstable overall, with fragile or even deflationary consumer trends in Europe, emerging markets undermined by volatile currencies, and difficulties specific to a few major markets, in particular the CIS. In 2015, Danone also anticipates marked but varied trends in the cost of major strategic raw materials, particularly milk; lower prices in Europe and the United States in the first half, with a rebound likely in the second half of the year, and gradual price increases in emerging countries all year long. Altogether, Danone anticipates a moderate rise in the cost of main raw materials and packaging in 2015. Sees slight growth in trading operating margin in 2015.
06:22 EDTDANOYDanone reports FY14 EPS EUR2.62
Subscribe for More Information
06:18 EDTDANOYDanone warns of volatility in years ahead, sees 'difficult' conditions in 2015
Subscribe for More Information
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
05:36 EDTNSRGYNestle aims to achieve organic growth of around 5%
Subscribe for More Information
05:35 EDTNSRGYNestle reports FY14 organic growth of 4.5%
Nestlé'sFY14 organic growth was 4.5%, composed of 2.3% real internal growth and 2.2% pricing. Sales were CHF 91.6B, down 0.6%, impacted by negative foreign exchange of -5.5%. Acquisitions, net of divestitures, added 0.4% to sales.
February 18, 2015
10:05 EDTDANOYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
06:01 EDTDANOYDanone upgraded to Neutral from Underperform at Exane BNP Paribas
Subscribe for More Information
February 17, 2015
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
07:15 EDTMJNConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use